NCT04540770View on ClinicalTrials.gov

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

March 4, 2022

Study Completion Date

January 19, 2024

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

HuL001

Anti-ENO1 monoclonal antibody

Trial Locations (2)

Unknown

Mackay Memorial Hospital, New Taipei City

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

HuniLife Biotechnology, Inc.

INDUSTRY